Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


ACS Meeting News

ACS to honor 2018 Heroes of Chemistry awardees in Boston

Developments have made significant contributions to human health and solar energy

by Linda Wang
August 17, 2018


Credit: DuPont
DuPont’s Solamet coating is used to improve the performance of solar panels, such as these being installed on a roof.

Four teams of industrial chemical scientists from Astrazeneca, DuPont, Pfizer, and Seattle Genetics will be honored with the 2018 Heroes of Chemistry awards on Sunday, Aug. 19, at the ACS national meeting in Boston.

Started in 1996, the Heroes program recognizes industrial chemical scientists whose innovative work has led to the development of commercially successful products, ingrained with chemistry, for the benefit of humankind.

“The Heroes of Chemistry Award honors the researchers who are often the unsung heroes in the lab, as well as the managers who support them,” says Diane Grob Schmidt, chair of the ACS Board Committee on Corporation Associates, which oversees the Heroes of Chemistry program. “These four teams clearly exemplify the characteristics of scientific excellence and sound business management, resulting in products, technologies, and processes that benefit humanity.”

The AstraZeneca team is being honored for its development of TAGRISSO (osimertinib), a targeted drug for patients with EGFR-mutated non-small cell lung cancer. The team consists of Raymond Finlay, Richard Ward, Sam Butterworth, and Michael Waring.

The DuPont team developed Solamet PV17x, a metallization paste that pioneered the use of lead tellurite chemistry for solar energy applications, such as solar panels. The awardees are Kurt Mikeska, Carmine (Charlie) Torardi, Paul VerNooy, Ken Hang, Alan Carroll, and Brian Laughlin.

The Pfizer team is being honored for its development of Inlyta (axitinib) for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. The team members include Robert Kania, Mike Varney, Michele McTigue, Steve Bender, Cindy Palmer, John Braganza, Michael R. Collins, Stephan Cripps, Scott Zook, Shu Yu, Jayaram Srirangam, Brian Chekal, Robert Singer, Steve Guinness, and Tony Campeta.

The team at Seattle Genetics developed ADCETRIS (brentuximab vedotin), which uses the company’s industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. The team members are Peter Senter, Clay Siegall, Brian Toki, Associate Medical Director, Medical Affairs, Seattle Genetics, Svetlana O. Doronina, Brian Mendelsohn, and Timothy D. Bovee.



This article has been sent to the following recipient:

Leave A Comment

*Required to comment